[Skip to Content]
[Skip to Content Landing]
Citations 0
May 25, 2005

Detection of Bladder Cancer Using a Proteomic Assay—Reply

Author Affiliations

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2005;293(20):2466-2467. doi:10.1001/jama.293.20.2467-b

In Reply: Patients enrolled in the study investigating the NMP22 assay were evaluated with cystoscopy because of the presence of risk factors that are associated with bladder cancer. Of the 1331 individuals, 91.6% (1220/1331) had hematuria, the most common symptom of bladder cancer. Other risk factors/symptoms included smoking, exposure to carcinogens, and dysuria. Many patients had more than 1 factor (565/1331 [42.4%]), and none were enrolled due to smoking history alone. The enrolling physicians believed that the patients were at sufficient risk to be screened for bladder cancer.

First Page Preview View Large
First page PDF preview
First page PDF preview